Navigation Links
Pfizer Plans Regulatory Submissions of Bosutinib in Chronic Myeloid Leukemia

NEW YORK, Dec. 3, 2010 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) announced today it is planning regulatory submissions of bosutinib in patients with chronic myeloid leukemia (CML) based on data from a clinical program evaluating the compound in newly diagnosed and previously treated patients.  These regulatory submissions are planned for 2011.


Pfizer has begun the process of preparing a Marketing Authorization Application (MAA) for submission to the European Medicine Agency (EMA) for bosutinib as a treatment option for patients with newly diagnosed Philadelphia chromosome positive (Ph+) CML.  The submission will be based on the results of the ongoing, Phase 3, randomized, open-label study of bosutinib versus imatinib in newly diagnosed patients with chronic phase Ph+ CML, called the BELA (Bosutinib Efficacy and safety in chronic myeloid LeukemiA) study.(1)

The Company has also had discussions with the United States (U.S.) Food and Drug Administration (FDA) regarding a possible regulatory submission for the use of bosutinib in the treatment of previously treated Ph+ CML patients. This submission would be based on the pending 24-month efficacy and safety data in the primary cohort of Study 200, which consists of more than 200 previously treated CML patients. Study 200 is a single arm study of bosutinib in over 500 patients with previously treated Ph+ CML, including patients resistant or intolerant to imatinib as well as patients who have become refractory to dasatinib or nilotinib.(2) Currently, there are no approved therapies available for CML patients who fail dasatinib or nilotinib in second line.(3,4,5)

"We are excited about the potential opportunities to bring bosutinib to market for patients with CML given the need for options in this patient population," said Garry Nicholson, president and general manager of the Pfizer Oncology business unit. "Our ongoing analysis of the bosutinib clinical development program reinforces our belief that bosutinib may provide benefit for patients living with CML, and we are working closely with health authorities and other experts toward our goal of making this promising compound available to patients who need it."

Further details of the BELA study and Study 200 will be presented at the upcoming 52nd Annual Meeting of the American Society of Hematology (ASH) (Abstract #208,(1) December 6 and Abstract #892,(2) December 7, respectively).

About Bosutinib

Bosutinib is an investigational oral dual Src and Abl kinase inhibitor.(1) It is believed that by dual inhibition of the Src and Abl tyrosine kinases, bosutinib may inhibit signaling in CML cells that allows the cells to grow, survive and reproduce.(6)

About Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML), one of the four main types of leukemia,(7) accounts for 15 percent of all leukemias worldwide.(8) A hallmark of CML is an abnormal chromosome known as the Philadelphia Chromosome, a DNA mutation that initiates a series of events leading to the development of Bcr-Abl, a tyrosine kinase that causes CML cells to grow and reproduce rapidly.(9)

Pfizer's Commitment to Hematology

Pfizer Oncology is committed to developing therapies to treat a variety of hematologic malignancies in both adult and pediatric patient populations.  Collectively, hematologic cancers represent the fifth most commonly occurring cancers and the second leading cause of cancer death. While there have been significant advancements in the treatment of hematologic cancers, there continues to be a need for new therapeutic approaches, both for newly diagnosed patients and relapsed patients. In order to deliver new options that target specific hematologic abnormalities and mutations, it is important to understand the molecular subtypes and genetic variations associated with hematologic cancers. Pfizer Oncology has biologics and small molecules in clinical development across a number of hematologic malignancies.

About Pfizer Oncology

Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide.  Our strong pipeline, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. Pfizer Oncology has biologics and small molecules in clinical development and more than 100 clinical trials underway. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments, and licensing partners, Pfizer Oncology strives to cure or control cancer with breakthrough medicines, to deliver the right drug for each patient at the right time.   For more information please visit  

DISCLOSURE NOTICE: The information contained in this release is as of December 3, 2010. Pfizer assumes no obligation to update  forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about certain potential indications for bosutinib, an oncology product candidate, including their potential benefits and the planned timing of regulatory submissions for such indications, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development, including with regard to the pending 24-month data from Study 200 and the ability of the Company to meet anticipated regulatory submission dates; decisions by regulatory authorities regarding whether and when to approve any drug applications that may be filed for any such indications as well as their decisions regarding labeling and other matters that could affect their availability or commercial potential; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.

(1) ASH Accepted Abstract #208. An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Oral Presentation. Carlo Gambacorti- Presenter. 52nd American Society of Hematology Annual Meeting. Orlando, FL. December 4-7, 2010

(2) ASH Accepted Abstract #892. Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib. Oral Presentation.  H. J. Khoury - Presenter. 52nd American Society of Hematology Annual Meeting. Orlando, FL. December 4-7, 2010.

(3) GLEEVEC. Prescribing Information. Novartis. East Hanover, NJ. 2010.

(4) SPRYCEL Prescribing Information. Bristol-Myers Squibb. Princeton, NJ. 2010.

(5) TASIGNA Prescribing Information. Novartis. East Hanover, NJ. 2007.

(6) Konig H et al. Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells. Cancer Research. 2008; 68: 9624-9633.

(7) National Cancer Institute. What you need to know about leukemia – Types of Leukemia. Available here: Accessed  November 16, 2010.

(8) Jabbour E et al. Targeted Therapy in Chronic Myeloid Leukemia. Expert Review of Anticancer Therapy. 2008; 8: 99-110.

(9) American Cancer Society. Detailed Guide: Leukemia – Chronic Myeloid (Myelogenous). Available at:  Accessed  November 16, 2010.

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
2. Pfizer Launches New Advil® Congestion Relief and Offers 100 Holiday Shoppers Literal Decongestion From Black Friday Crowds
3. Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco
4. Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
5. Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
6. Pfizer Declares an 18-Cent Fourth-Quarter 2010 Dividend
7. Pfizers Lyrica® (Pregabalin) Capsules CV Receives Approval for Treatment of Peripheral Neuropathic Pain In Japan
8. Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.
9. Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil
10. Biocon and Pfizer Enter Into Global Commercialization Agreement
11. Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  DILON Diagnostics and GE ... an agreement for DILON to distribute GE,s Discovery NM750b ... globe. The signing of this distribution agreement will provide Dilon,s ... Breast Imaging system and is considered an initial step ... healthcare solutions for clinicians and their patients. ...
(Date:11/24/2015)... Sectra (STO: SECT B) announces that ... agreement to deploy Breast Imaging PACS in its ... Breast Center a future-proof platform capable of expanding with the ... that Breast Center of Acadiana has entered into ... in its two freestanding imaging centers. This investment will ...
(Date:11/24/2015)... --  HeartWare International, Inc . (NASDAQ: HTWR ), ... that are revolutionizing the treatment of advanced heart failure, ... Doug Godshall is scheduled to present at the ... December 1, 2015 at 3:00 p.m. ET.  The conference ... York . .  A ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Smiles by Stevens is pleased to ... facial wrinkling. While many patients are aware of the benefits of Botox® in the ... to those suffering with discomfort, soreness, and pain as a result of Jaw Tension, ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, ... from Bronx, N.Y. “I thought there had to be a convenient and comfortable way ... , The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately ... has undertaken significant expansion of its current state of the art research, development ... PharmaTech’s strategy to increase its manufacturing capacity as well as to support its ...
(Date:11/25/2015)... San Mateo, CA (PRWEB) , ... November 25, 2015 , ... ... $15,000 in prizes were awarded to winners of the Create Real Impact awards. ... and creative expression to help stem the tide of distracted and reckless driving, the ...
(Date:11/24/2015)... , ... November 24, 2015 , ... New patients who ... a referral for dental implants at her Mississauga, ON practice. Dr. Williams ... in the placement of dental implants. , Missing teeth can lead to a ...
Breaking Medicine News(10 mins):